
DaVita
DVA · NYSE · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $11,0 bn
- Div. yield
- —
- Year to date
- +53,2%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
5 ✓ · 3 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 11,9 | 13,1 | 25,1 |
| Forward P/E | 11,8 | — | 16,2 |
| PEG | 0,4 | — | 2,2 |
| P/S | 0,8 | 0,8 | 2,2 |
| EV/EBITDA | 7,6 | 7,6 | 17,3 |
| P/FCF | 8,5 | — | 19,5 |
| P/B | 90,7 | 9,8 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 13 analysts
- Buy
- 7
- Hold
- 5
- Sell
- 1
Beat the EPS forecast in 3 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 3,64 | 3,40 | Down −6,6% |
| Q2 2026 | 3,92 | 4,02 | Up +2,5% |
| Q1 2026 | 2,34 | 2,87 | Up +22,6% |
| Q4 2025 | 3,19 | 3,40 | Up +6,7% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,58 bn | 3,55 bn | 3,42 bn | 3,62 bn | 3,42 bn | 3,38 bn | 3,22 bn | 3,29 bn | 3,26 bn | 3,19 bn | 3,07 bn | 3,15 bn |
| EPS | 3,40 | 4,02 | 2,87 | 3,22 | 2,04 | 2,58 | 2,00 | 3,07 | 2,50 | 2,50 | 2,65 | 1,62 |
| Margin | 6,2% | 7,5% | 5,8% | 6,5% | 4,4% | 5,9% | 5,1% | 7,9% | 6,6% | 7,0% | 7,8% | 4,8% |
| FCF | 359 m | 320 m | 219 m | 395 m | 675 m | 203 m | 36,8 m | 377 m | 671 m | 674 m | −256 m | 326 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $523 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| berkshire hathaway inc27 Oct 2026 · sale | $69,0 m | 382 563 | $180,43 |
| berkshire hathaway inc31 Jul 2026 · sale | $36,5 m | 182 980 | $199,55 |
| rodriguez javier16 Jun 2026 · sale | $8,25 m | 39 407 | $209,28 |
| waters kathleen alyce15 Jun 2026 · sale | $1,35 m | 6 455 | $209,17 |
| waters kathleen alyce15 Jun 2026 · sale | $1,86 m | 8 950 | $207,84 |
| rodriguez javier15 Jun 2026 · sale | $6,29 m | 30 000 | $209,50 |
| hearty james o15 May 2026 · sale | $2,91 m | 15 000 | $193,98 |
| maughan david paul12 May 2026 · sale | $2,68 m | 13 456 | $199,25 |
| maughan david paul11 May 2026 · sale | $1,41 m | 7 073 | $199,15 |
| ackerman joel7 May 2026 · sale | $9,89 m | 51 471 | $192,10 |
| hearty james o6 May 2026 · sale | $381 916 | 2 184 | $174,87 |
| buffett warren e1 May 2026 · sale | $183 m | 1 220 376 | $149,84 |
| buffett warren e29 Jan 2026 · sale | $200 m | 1 658 480 | $120,56 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NYSE
- Country
- US
- IPO date
- 31 Oct 1995
- Website
- www.davita.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
UHSUniversal Health Services | $197,80 | 78★★★★★★★★★would consider | 7,8 | +8,0% | 8,0% |
PODDInsulet Corporation | $145,29 | 89★★★★★★★★★★would consider | 24,7 | +26,5% | 13,4% |
ALGNAlign Technology | $165,98 | 89★★★★★★★★★★would consider | 24,1 | +4,4% | 11,8% |
COOCooper Companies (The) | $61,88 | 89★★★★★★★★★★would consider | 20,9 | +4,7% | 13,5% |
HSICHenry Schein | $84,96 | 83★★★★★★★★★would consider | 22,6 | +6,2% | 3,1% |
Ratio — a score by our methodology, not an investment recommendation.




